…
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Apogee Therapeutics, Inc. is a small publicly listed biopharmaceutical company; public disclosures are limited, but it appears focused on development of prescription therapeutics. Major long-term growth drivers may include clinical progress, regulatory approvals, strategic collaborations and eventual commercialization of approved products, which could support revenue and valuation expansion. Investors may find the company attractive for potential upside from successful development programs and niche market opportunities.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -255.56M | -182.13M | -83.98M | -39.78M |
| Net income | -255.84M | -182.15M | -83.98M | -39.78M |
| Selling general administrative | 70.88M | 49.01M | 24.58M | 2.94M |
| Gross profit | -1.42M | -0.19M | - | - |
| Reconciled depreciation | 1.42M | 0.19M | - | - |
| Ebit | -285.60M | -216.87M | -93.10M | -30.76M |
| Ebitda | -284.18M | -216.68M | -93.00M | -30.73M |
| Depreciation and amortization | 1.42M | 0.19M | 0.09M | 0.03M |
| Operating income | -285.60M | -216.87M | -93.00M | -30.73M |
| Other operating expenses | 285.60M | 216.87M | 93.00M | 30.73M |
| Interest expense | - | - | 0.00M | 9.15M |
| Tax provision | 0.28M | 0.02M | - | - |
| Interest income | 30.03M | 34.74M | 9.02M | 0.09M |
| Net interest income | 30.03M | 34.74M | 9.02M | -9.06M |
| Income tax expense | 0.28M | 0.02M | -0.09M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 284.18M | 216.87M | 93.00M | 30.73M |
| Cost of revenue | 1.42M | 0.19M | - | - |
| Total other income expense net | 30.03M | 34.74M | 9.02M | -9.06M |
| Net income from continuing ops | -255.84M | -182.15M | -83.98M | -39.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 937.13M | 753.95M | 401.40M | 152.06M |
| Other current assets | 11.17M | 4.36M | 2.95M | 0.06M |
| Total liab | 33.25M | 37.16M | 21.49M | 9.98M |
| Total stockholder equity | 903.88M | 716.79M | 379.91M | -39.78M |
| Other current liab | 23.18M | 24.25M | 17.31M | 9.56M |
| Common stock | 0.00M | 0.00M | - | 4.39M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -561.76M | -305.92M | -123.77M | -39.78M |
| Cash | 131.55M | 141.79M | 118.32M | 151.89M |
| Total current liabilities | 27.91M | 28.56M | 20.56M | 9.98M |
| Net debt | -122.70M | -129.96M | -116.28M | -151.89M |
| Short term debt | 3.50M | 3.23M | 1.10M | - |
| Short long term debt total | 8.85M | 11.83M | 2.03M | - |
| Other stockholder equity | 1464.56M | 1021.79M | 503.35M | 39.78M |
| Total current assets | 741.36M | 529.71M | 398.41M | 152.06M |
| Long term investments | 172.73M | 210.42M | - | - |
| Short term investments | 598.64M | 378.86M | 277.14M | 0.00M |
| Net receivables | - | 4.70M | - | - |
| Accounts payable | 1.22M | 1.07M | 2.14M | 0.42M |
| Accumulated other comprehensive income | 1.08M | 0.92M | 0.33M | -221.65M |
| Non currrent assets other | 181.40M | 0.50M | 0.10M | - |
| Non current assets total | 195.78M | 224.24M | 3.00M | 0.00M |
| Capital lease obligations | 8.85M | 11.83M | 2.03M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | -174.43M | -300.46M | -273.91M | 0.00M |
| Total cashflows from investing activities | -179.57M | -300.46M | - | - |
| Total cash from financing activities | 396.49M | 495.11M | 315.39M | 0.18M |
| Net income | -255.84M | -182.15M | -83.98M | -39.78M |
| Change in cash | -10.53M | 23.47M | -33.57M | -16.24M |
| Begin period cash flow | 142.08M | 118.61M | 151.89M | 168.13M |
| End period cash flow | 131.55M | 142.08M | 118.32M | 151.89M |
| Total cash from operating activities | -227.45M | -171.17M | -74.76M | -16.43M |
| Issuance of capital stock | 389.63M | 493.48M | 315.39M | 168.32M |
| Depreciation | 1.42M | 0.19M | - | - |
| Other cashflows from financing activities | 396.49M | 1.63M | 0.32M | 0.18M |
| Capital expenditures | 5.15M | 1.15M | 0.17M | 0.00M |
| Change in working capital | -15.48M | -2.00M | 6.11M | 9.81M |
| Stock based compensation | 46.28M | 23.33M | 6.10M | 2.14M |
| Other non cash items | -3.82M | -10.55M | -2.98M | 11.40M |
| Free cash flow | -232.60M | -172.33M | -74.93M | -16.43M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Thomas Henderson M.D. | CEO & Director | 1990 |
| Ms. Jane Pritchett V. Henderson | Chief Financial Officer | 1966 |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer | 1986 |
| Dr. Rebecca Dabora Ph.D. | Chief Technical Officer | 1959 |
| Ms. Noel Kurdi | Vice President of Investor Relations | NA |
| Mr. Matthew Batters J.D. | General Counsel | 1976 |
| Ms. Emily Cox | VP & Head of People | NA |
| Ms. Wendy Aspden-Curran | Senior Vice President of Clinical Operations | NA |
| Dr. Drew Badger Ph.D. | Senior VP and Head of Regulatory Affairs & Toxicology | NA |
| Ms. Monica Forbes | Senior Vice President of Finance | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.